|
AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. ‘Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually,’ Astra notes. Earlier this year, AZD0780 progressed into phase II trials in patients with dyslipidaemia. Current stock price: 12,052.00 pence 12-month change: up 4.8% Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
